Loading stock data...

Gennex Laboratories Limited

BSE: GENNEX

BSE
12.10 0.92 (8.23%)

Prev Close

11.18

Open Price

11.38

Volume

708,680

Today Low / High

11.18 / 12.15

52 WK Low / High

10.84 / 19

Range

11 - 13

The stock is currently available for trading on the Bombay Stock Exchange (BSE). Its price is 12.1, reflecting a change of 0.92 (8.22898%). The expected target range on the BSE is 11 - 13. The stock is showing an upward trend on the BSE, making it an appealing option for investors looking for growth in their portfolio.

01 Oct 11.38 6.33%
30 Sep 11.28 -0.89%
29 Sep 11.83 -3.38%
26 Sep 11.89 -0.67%
25 Sep 12.05 -1.41%
24 Sep 12.47 -3.69%
23 Sep 12.50 -0.24%
22 Sep 12.61 -0.87%
19 Sep 12.99 -2.93%
18 Sep 12.41 4.19%
17 Sep 12.69 -2.44%
16 Sep 11.90 5.80%
15 Sep 11.39 3.86%
12 Sep 11.42 -0.70%
11 Sep 11.50 -1.13%
10 Sep 11.39 0.53%
09 Sep 11.32 0.35%
08 Sep 11.45 -1.57%
05 Sep 11.58 -1.99%
04 Sep 11.57 -0.78%

Gennex Laboratories Limited Graph

Gennex Laboratories Limited Price Target Predictions: Bullish vs. Bearish Scenarios with Ranges

If you are looking for the target price for Gennex Laboratories Limited T1, T2, T3 for both Bullish and Bearish scenarios, here it is. For Bullish: T1, T2, T3. For Bearish: T1, T2, T3. The stock current price is 12.10, with potential price targets ranging from T1, T2, and T3 in both directions based on market conditions.

Scenario Price Target Range
Bullish Scenario 12.10 12.22 11.00 - 13.44
12.34 9.87 - 14.81
12.46 8.72 - 16.20
Bearish Scenario 12.10 11.98 10.78 - 13.18
11.86 9.49 - 14.23
11.74 8.22 - 15.26

Overview of Gennex Laboratories Limited

ISIN

INE509C01026

Industry

Medical - Pharmaceuticals

Vol.Avg

543,366

Market Cap

2,796,937,264

Last Dividend

0

Official Website

Visit Website

IPO Date

2001-04-26

DCF Diff

19.08

DCF

-7

Financial Ratios Every Investor Needs

Stock Dividend of GENNEX

Date Label Adj Dividend Dividend Record Date Payment Date Declaration Date
2001-09-10 September 10, 01 0.095402 0.9998

Stock Rating Details for GENNEX

Metric Value Recommendation
Overall Rating C- Strong Sell
DCF Score 1 Strong Sell
ROE Score 1 Strong Sell
ROA Score 1 Strong Sell
Debt-to-Equity (DE) Score 1 Strong Sell
Price-to-Earnings (PE) Score 3 Neutral
Price-to-Book (PB) Score 1 Strong Sell

Annual Financial Income Report

Date Revenue Co.Rev GP GPR R&D Expenses G&A Expenses Operating Income Net Income EPS EBITDA NIR
2025-03-31 137.90 Cr 107.42 Cr 30.48 Cr 0.2210 0.00 Cr 0.00 Cr 14.73 Cr 16.12 Cr 0.76 27.15 Cr 0.1169
2024-03-31 86.71 Cr 59.01 Cr 27.70 Cr 0.3194 0.00 Cr 0.54 Cr 14.66 Cr 13.18 Cr 0.67 21.94 Cr 0.1519
2023-03-31 65.60 Cr 39.91 Cr 25.69 Cr 0.3916 0.00 Cr 0.51 Cr 3.81 Cr 4.92 Cr 0.34 8.65 Cr 0.0750
2022-03-31 61.18 Cr 38.67 Cr 22.50 Cr 0.3679 0.00 Cr 0.39 Cr 4.69 Cr 3.92 Cr 0.30 6.76 Cr 0.0641
2021-03-31 59.63 Cr 36.70 Cr 22.93 Cr 0.3846 0.00 Cr 0.33 Cr 5.78 Cr 4.04 Cr 0.30 6.69 Cr 0.0677

Annual Financials Balance Sheet

Date C&C Equ. Tot. Assets Tot. Liab. Stock. Equity Tot. Debt Net Debt Inv. PP&E (Net) Curr. Def. Rev. Non-Curr. Def. Rev. LT Invest. Curr. Liab.
2025-03-31 55.57 Cr 256.04 Cr 61.45 Cr 186.6868 Cr 10.22 Cr -45.35 Cr 35.94 Cr 61.83 Cr 0.00 Cr 0.00 Cr 0.01 Cr 44.5528 Cr
2024-03-31 60.23 Cr 229.99 Cr 53.52 Cr 170.3815 Cr 18.94 Cr -41.29 Cr 25.17 Cr 55.02 Cr 0.00 Cr 0.00 Cr 0.01 Cr 40.3048 Cr
2023-03-31 0.56 Cr 132.32 Cr 45.80 Cr 81.3499 Cr 1.05 Cr 0.49 Cr 15.69 Cr 67.65 Cr 11.60 Cr 0.00 Cr 0.01 Cr 29.5130 Cr
2022-03-31 7.49 Cr 68.03 Cr 24.21 Cr 43.8152 Cr 10.12 Cr 2.63 Cr 7.74 Cr 13.70 Cr 0.16 Cr 0.00 Cr 6.83 Cr 24.2081 Cr
2021-03-31 0.19 Cr 58.90 Cr 19.19 Cr 39.7097 Cr 7.36 Cr 7.17 Cr 5.02 Cr 14.13 Cr 0.37 Cr -0.02 Cr 6.83 Cr 19.0237 Cr

Annual Financials Cash Flow Statement

Date Operating Cash Investing Cash Financing Cash Free Cash Cash Change Cash at End CapEx Income Debt Repay Dividends Inventory
2025-03-31 -4.8338 Cr -8.7471 Cr 8.1747 Cr -13.7806 Cr 34.5939 Cr 55.5689 Cr -8.9468 Cr 16.1230 Cr 8.1747 Cr 0.0000 Cr -10.7650 Cr
2024-03-31 -46.6864 Cr 18.9134 Cr 73.6838 Cr -46.6864 Cr 45.9109 Cr 60.9750 Cr 0.0000 Cr 13.1750 Cr -3.0717 Cr 0.0000 Cr -9.4825 Cr
2023-03-31 -14.4505 Cr -0.7652 Cr 21.3542 Cr -16.6728 Cr 6.1384 Cr 14.4513 Cr -2.2223 Cr 6.0112 Cr -8.0522 Cr 0.0000 Cr -7.2358 Cr
2022-03-31 6.6361 Cr -1.2612 Cr 1.8689 Cr 6.2464 Cr 7.2438 Cr 8.3129 Cr -0.3897 Cr 5.2757 Cr -0.9537 Cr 0.0000 Cr -2.7182 Cr
2021-03-31 -1.4371 Cr -0.0250 Cr 1.6186 Cr -1.5159 Cr 0.1565 Cr 1.0691 Cr -0.0788 Cr 5.0622 Cr 2.3621 Cr 0.0000 Cr 2.4188 Cr

Quarterly Financial Income Report

Date Revenue Co.Rev GP GPR Operating Income Net Income EPS EBITDA NIR
2025-06-30 34.18 Cr 22.20 Cr 11.98 Cr 0.3505 4.57 Cr 5.02 Cr 0.22 7.35 Cr 0.1468
2025-03-31 40.33 Cr 34.92 Cr 5.41 Cr 0.1342 1.47 Cr 2.32 Cr 0.11 5.85 Cr 0.0576
2024-12-31 37.71 Cr 27.68 Cr 10.03 Cr 0.2660 6.66 Cr 4.64 Cr 0.22 7.15 Cr 0.1232
2024-09-30 31.55 Cr 19.31 Cr 12.24 Cr 0.3879 7.24 Cr 4.83 Cr 0.21 7.45 Cr 0.1530
2024-06-30 28.32 Cr 20.54 Cr 7.78 Cr 0.2746 3.78 Cr 4.66 Cr 0.21 6.69 Cr 0.1645

Quarterly Financials Balance Sheet

Date Cash & Equiv. Short-Term Inv. Cash & Short-Term Net Receivables Inventory Total Curr. Assets PP&E (Net) Total Assets Total Liabilities
2025-03-31 55.57 Cr 0.00 Cr 55.57 Cr 14.16 Cr 35.94 Cr 181.13 Cr 61.83 Cr 256.04 Cr 61.45 Cr
2024-12-31 0.00 Cr 0.00 Cr 52.54 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr -186.49 Cr
2024-09-30 52.54 Cr 0.00 Cr 52.54 Cr 54.21 Cr 40.16 Cr 176.22 Cr 64.01 Cr 244.30 Cr 57.81 Cr
2024-06-30 0.00 Cr 0.00 Cr 60.98 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr -176.46 Cr
2024-03-31 60.23 Cr 0.74 Cr 60.98 Cr 17.81 Cr 25.17 Cr 161.81 Cr 55.02 Cr 229.99 Cr 53.52 Cr

Quarterly Financials Cash Flow Statement

Date Net Income Operating Cash Flow Investing Cash Flow Financing Cash Flow Net Cash Change Cash at End Cash at Beginning CapEx Free Cash Flow
2024-12-31 4.64 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr
2024-09-30 5.37 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr
2024-06-30 4.66 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr
2024-03-31 4.50 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr
2023-12-31 2.76 Cr 0.91 Cr 0.00 Cr 0.00 Cr 0.91 Cr 10.68 Cr 9.77 Cr 0.00 Cr 0.91 Cr

Splits History

Date Label Split Ratio
2022-07-21 July 21, 22 131:125
2009-12-14 December 14, 09 10:1

Similar Stocks: Medical - Pharmaceuticals

Company Name Symbol Price Market Cap Volume
MedPlus Health Services Limited MEDPLUS ₹741.10 ₹88,742,053,847.00 ₹95,115.00

Key Executives

Chairman & MD
Mr. Arihant Baid

Gender: male

Year Born: 1986

Chief Financial Officer
Mr. Akkali Santosh Kumar

Gender: male

Year Born:

Chief Operating Officer
Mr. K. V. L. N. Bhaswanth

Gender: male

Year Born:

Company Secretary & Compliance Officer
Mr. Dinesh Kumar Kejriwal

Gender: male

Year Born: 1964

FAQs about Gennex Laboratories Limited

Who is the CEO of the company?

The CEO is Arihant Baid.

What is the current market price of the stock?

The current price is ₹12.10.

What is the 52-week price range?

The range is ₹10.84-19.

What is the market capitalization of the company?

The market capitalization is ₹279.69 crores.

What is the Price-to-Earnings (P/E) ratio?

The P/E ratio is 16.64.

Which sector does the company belong to?

The company operates in the Healthcare sector.

What does the company do?

Overview of Gennex Laboratories Limited (ISIN: INE509C01026) is a leading Medical - Pharmaceuticals in India. With a market capitalization of ₹279.69 crores and an average daily volume of 543,366 shares, it operates in the Medical - Pharmaceuticals. The company last declared a dividend of ₹0.